ÀÏÂ÷¼º ÁßÃ߽Űæ°è ¸²ÇÁÁ¾ÀÇ °æ¸· ³» Rituximab Ä¡·á 2¿¹
Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 2È£ p.224 ~ p.228
Àå¿ëÈ£(Jang Yong-Ho) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
ÇÏÅÂȯ(Ha Tae-Hwan) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
±è´öÈñ(Kim Deok-Hee) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
±è¼º·Ï(Kim Sung-Rok) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
À¯¿µÁø(Yuh Young-Jin) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
¼Õº´¼®(Sohn Byeong-Seok) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ³»°ú
ÀÌÇý¶õ(Lee Hye-Ran) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÏ»ê¹éº´¿ø ³»°ú
Abstract
Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin¡¯s lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.
Å°¿öµå
Primary CNS lymphoma, Intrathecal immunotherapy, Rituximab, Lymphomatous meningitis
KMID :
0882420140870020224
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)